Canadian clinical trial registry

Search results

Information is also accessible through the patient and families tab. Family friendly summaries are created and reviewed by our advocacy partners. The information is updated to the best of our knowledge but might not reflect the latest information. Note that most studies are only available at a limited number of sites, please click on ‘further information’ for details. Studies, particularly early phase trials, may also temporarily close to enrolment or not have slots available for all treatment groups. In all cases, study teams at individual C17 centres will have the most up-to-date information.

107 results found

Title
Status

 

VICTORY (OZM-138) - VICTORY: A Pilot Study to Investigate Safety and Efficacy of Weekly Combination of Intravenous Vinblastine With Oral Type II RAF Inhibitor Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas

Open

VICTORY (OZM-138) - VICTORY: A Pilot Study to Investigate Safety and Efficacy of Weekly Combination of Intravenous Vinblastine With Oral Type II RAF Inhibitor Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas

Go to Health Care Provider version

DiagnosisLow-grade GliomaStudy StatusOpen
PhaseI
AgeUp to 25 YearsRandomisationNO
Line of treatmentDisease relapse or progression
Routes of Treatment AdministrationDrug: Tovorafenib oral (immediate-release tablets or powder for reconstitution) Drug: Vinblastine IV
Last Posted Update2025-09-02
ClinicalTrials.gov #NCT06381570
International Sponsor
IIT - The Hospital for Sick Children
Principal Investigators for Canadian Sites
The Hospital for Sick Children - Dr. Uri Tabori
HHSC/McMaster - Dr. Adam Fleming
CHEO - Dr. Nirav Thacker
Stollery Children's Hospital - Dr. Liana Nobre
BC Children's Hospital - Dr. Sylvia Cheng
CHU Ste Justine - Dr. Sébastien Perreault
Centres
Medical contact

Dr. Daniel Morgenstern

daniel.morgenstern@sickkids.ca

Social worker/patient navigator contact

Karen Fung 

karen.fung@sickkids.ca

Clinical research contact

New Agent and Innovative Therapies (NAIT) 

nait.info@sickkids.ca

 

Medical contact
Dr. Carol Portwine
 
Social worker/patient navigator contact
Jane Cassano 
 
Clinical research contact
Sabrina Millson
 
 
Medical contact
Dr. Donna Johnston
 
Dr. Lesleigh Abbott
 
Dr. Nirav Thacker
 
Social worker/patient navigator contact
Sherley Telisma
 
Clinical research contact
Isabelle Laforest
 
Medical contact
Dr. Sarah McKillop
Dr. Sunil Desai

 

 

Social worker/patient navigator contact
Danielle Sikora
 Michelle Woytiuk 
Jaime Hobbs
Clinical research contact
Amanda Perreault
Medical contact
Rebecca Deyell

 

Social worker/patient navigator contact
Ilana Katz 

 

Clinical research contact
Hem/Onc/BMT Clinical Trials Unit

 

Medical contact
Dr. Henrique Bittencourt
Dr. Monia Marzouki
Dr. Sebastien Perreault (neuro-onc)
 
Social worker/patient navigator contact
Marie-Claude Charrette
 
Clinical research contact
Marie Saint-Jacques
 

 

 

Study Description

 This study is eligible for STEP-1 funding. Find more information here

 

VICTORY is an early phase study for patients under 25 years who have a type of brain tumor called low grade glioma (LGG) that coms back or gets worse (recurrent or progressive). To participate on this study, the LGG must have certain genetic changes called CRAF or BRAF alterations.

The study has two parts:

Phase A: We are figuring out the best dose of a combination of two medicines, vinblastine and tovorafenib. Patients will take these medicines for a certain number of months, then just tovorafenib for a few more months. Their progress will be checked regularly with scans.

Phase B: After we find the right dose in Phase A, we'll test how well the combination of these drugs works. Patients will take these medicines for a certain number of months, then just tovorafenib for a few more months. Their progress will be checked regularly with scans.

Patients will be in the study for about two years unless their tumor gets worse (disease progression), they have bad side effects or they decide to withdrawal from the study.

Inclusion Criteria
  • Patients must be less than or equal to 25 years of age at the time of enrollment
  • Patient and/or their parent/guardian must sign an informed consent form to be enrolled on study
  • Patients must have a diagnosis of low grade glioma (LGG) with a genetic alteration called BRAF or CRAF alteration that has come back (recurrent) or not responded to previous treatment (progressive)
  • Patients must have completed at least 1 other therapy prior to enrollment on this study and recovered from its effects.
  • Patients must have adequate performance status (daily activities which they are able to do) 
  • Must have adequate organ function in bone marrow, kidneys, liver, heart and thyroid
  • Willingness of male and female patients with reproductive potential to use double effective birth control methods, defined as one used by the patient and another by his/her partner, for the duration of treatment and for 180 days following the last dose of study drug. 
  • Ability to swallow tablets or liquid, or gastric access via a nasal or gastric tube.

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team.

PBTC-060 - A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Closed to enrollment

PBTC-060 - A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Go to Health Care Provider version

DiagnosisMedulloblastoma, Glioblastoma, Anaplastic Astrocytoma, Oligodendroglioma, Ependymoma, Diffuse Intrinsic Pontine GliomaStudy StatusClosed to enrollment
PhaseI
Age1 Year to 21 YearsRandomisationNO
Line of treatmentDisease relapse or progression
Routes of Treatment AdministrationBiological: SurVaxM (injection) 500 mcg (1 mL) SurVaxM emulsion with Montanide ISA 51. Sargramostim dose is 3.33 mcg/kg/dose for patients < 30 kg, and 100 mcg for patients ≥ 30 kg.
Last Posted Update2025-09-02
ClinicalTrials.gov #NCT04978727
International Sponsor
Pediatric Brain Tumor Consortium
Principal Investigators for Canadian Sites
The Hospital for Sick Children - Dr. Vijay Ramaswamy
Centres
Medical contact

Dr. Daniel Morgenstern

daniel.morgenstern@sickkids.ca

Social worker/patient navigator contact

Karen Fung 

karen.fung@sickkids.ca

Clinical research contact

New Agent and Innovative Therapies (NAIT) 

nait.info@sickkids.ca

 

 

 

Study Description

Patients on this study will receive 4 doses of a vaccine called SurVaxM. While vaccines are usually thought of as ways to prevent diseases, vaccines can also be used to treat cancer. SurVaxM is designed to tell the body's immune system to look for tumor cells that express a protein called survivin and destroy them. If the body's immune system knows to destroy cells that express survivin, it may help to control tumor growth and recurrence.

 

Inclusion Criteria
  • Participant must have one of the following tumors that has progressed or come back: 
    • Medulloblastoma
    • Glioblastoma multiforme 
    • Anaplastic astrocytoma
    • High-grade astrocytoma, NOS
    • Anaplastic oligodendroglioma
    • Anaplastic ependymoma
    • Ependymoma 
    • Diffuse Intrinsic Pontine Gliomas (DIPG)
  • Participant must be ≥ 1 year of age and ≤ 21 years of age at the time of screening.
  • Participant or parent/guardian must be willing to sign a consent form and complete the study related assessments.
  • Participants must have recovered from all previous cancer therapies. 
  • Must be up and about for around 60% of the patient's waking hours
  • Participants must meet all the blood work requirements 
  • You cannot be pregnant or become pregnant on this study. If you are able to have children, you must use an acceptable form of birth control. Abstinence is included. 

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team.

PBTC-049 - A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS Tumors Harboring MET Aberrations

Closed to enrollment

PBTC-049 - A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Medulloblastoma, High-Grade Glioma, Diffuse Intrinsic Pontine Glioma, and CNS Tumors Harboring MET Aberrations

Go to Health Care Provider version

DiagnosisRecurrent or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent or Refractory Malignant Glioma, Recurrent or Refractory Medulloblastoma, Recurrent or Refractory Primary Central Nervous System NeoplasmStudy StatusClosed to enrollment
PhaseI
Age6 Years to 21 YearsRandomisationN/A
Line of treatmentDisease relapse or progression
Routes of Treatment AdministrationDrug: Savolitinib (Oral) Other Names: AZD 6094 AZD6094 HMPL-504 Volitinib
Last Posted Update2025-09-02
ClinicalTrials.gov #NCT03598244
International Sponsor
National Cancer Institute (NCI)
Principal Investigators for Canadian Sites
The Hospital for Sick Children - Dr. Vijay Ramaswamy
Centres
Medical contact

Dr. Daniel Morgenstern

daniel.morgenstern@sickkids.ca

Social worker/patient navigator contact

Karen Fung 

karen.fung@sickkids.ca

Clinical research contact

New Agent and Innovative Therapies (NAIT) 

nait.info@sickkids.ca

 

 

 

Study Description

PBTC-049 tests a drug called savolitinib to see how well it works in children with these tumors. This drug has not been studied in children. The hope is that this drug may be a more effective treatment for these types of brain tumors in children.

Therefore, the primary goals of the study are to:

  • Determine which dose of savolitinib is safe for children
  • Learn what effects (good or bad) may occur when patients take savolitinib
  • Learn how the body processes savolitinib

(via: PBTC-049_Summary for patients & families_05-18-2020.pdf)

Inclusion Criteria
  • Patients with confirmed medulloblastoma, high-grade glioma, DIPG brain tumors, and other brain tumor types with a specific genetic marker, which continue to grow or have come back after the prior treatment may be eligible to participate.
  • Patients must be between 5-21 years of age.
  • Patients must have recovered from toxicities of all prior chemotherapy, immunotherapy, radiotherapy or any other treatment modality prior to entering this study.
  • Pregnant women and nursing mothers are excluded from this study
  • Patients or a parent/guardian must understand and sign a written consent form to participate
  • Patients and/or their families must agree to the study visit requirements outlined in the consent form

(via: PBTC-049_Summary for patients & families_05-18-2020.pdf)

Other inclusion criteria may apply and will be discussed with you by the study team.

PBTC-059 - Phase 1 Trial of Autologous HER2-specific CAR T Cells in Pediatric Patients With Refractory or Recurrent Ependymoma

Closed to enrollment

PBTC-059 - Phase 1 Trial of Autologous HER2-specific CAR T Cells in Pediatric Patients With Refractory or Recurrent Ependymoma

Go to Health Care Provider version

DiagnosisEpendymomaStudy StatusClosed to enrollment
PhaseI
Age1 Year to 22 YearsRandomisationNO
Line of treatmentDisease relapse or progression
Routes of Treatment AdministrationBiological: HER2 Specific CAR T Cell (IV) Phase 1 Arm: Patients receive lymphodepletion chemotherapy with cyclophosphamide IV daily on Days -7 to -6 and fludarabine IV daily on Days -5 to -1. Patients receive HER2 CAR T cells IV on Day 0. Treatment repeats every 8 to 12 weeks for 2 additional cycles in the absence of disease progression or unacceptable toxicity. Surgical Arm: Patients receive lymphodepletion chemotherapy with cyclophosphamide IV daily on Days -7 to -6 and fludarabine IV daily on Days -5 to -1. Patients receive HER2 CAR T cells IV on Day 0 followed by surgical tumor resection 4-6 weeks following HER2 CAR T cell infusion. Treatment repeats every 8 to 15 weeks for 2 additional cycles in the absence of disease progression or unacceptable toxicity.
Last Posted Update2025-09-02
ClinicalTrials.gov #NCT04903080
International Sponsor
Pediatric Brain Tumor Consortium
Principal Investigators for Canadian Sites
The Hospital for Sick Children - Dr. Joerg Krueger
Centres
Medical contact

Dr. Daniel Morgenstern

daniel.morgenstern@sickkids.ca

Social worker/patient navigator contact

Karen Fung 

karen.fung@sickkids.ca

Clinical research contact

New Agent and Innovative Therapies (NAIT) 

nait.info@sickkids.ca

 

 

 

Study Description

This study evaluates the safety of a type of treatment called HER2 CAR T cells (short for HER2 chimeric antigen receptor T cells). In addition to looking for side effects, we will study how well this treatment works against a brain tumor called ependymoma that has come back after treatment (recurrent) or has not responded well to treatment (progressive) in children. The HER2 CAR T cells used in this trial are made from the patient's own blood.

A new gene, called the HER2 CAR, will be inserted into patient's cells to allow them to recognize a protein on the tumor called HER2. These HER2-specific CAR T cells may be able to target and kill ependymoma tumors. This research is also studying how doable it is to provide this type of CAR T cell treatment to children being treated at different hospitals.

Inclusion Criteria
  • Participants must have a diagnosis of ependymoma that is has come back or progressed.
  • Patient must be ≥ 1 but ≤ 22 years of age at the time of enrollment for treatment.
  • Participants must be up and about for 60% of their waking hours
  • Patients must have received last dose of previous chemotherapy at least 21 days before enrollment.
  • Patient must meet all organ function, bone marrow function and laboratory criteria
  • The patient or parent/guardian can understand the consent and is willing to sign a written informed consent document according to institutional guidelines. Age- and developmentally appropriate assent should be obtained as required by institutional guidelines.

Additional inclusion and exclusion criteria applies and will be discussed with you by the study team.

ACNS1821 - A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)

Open

ACNS1821 - A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)

Go to Health Care Provider version

DiagnosisHigh-Grade Glioma (HGG) without H3 K27M mutationStudy StatusOpen
PhaseI/II
Age12 Months to 21 YearsRandomisationNO
Line of treatmentFirst line treatment
Routes of Treatment AdministrationDrug: Selinexor (oral) Radiation: Radiation therapy
Last Posted Update2025-08-27
ClinicalTrials.gov #NCT05099003
International Sponsor
National Cancer Institute (NCI)
Principal Investigators for Canadian Sites
The Hospital for Sick Children - Dr. Julie Bennett
BC Children's Hospital - Dr. Rebecca Deyell
CancerCare Manitoba - Dr. Ashley Chopek
CHU Quebec - Dr. Bruno Michon
CHU Ste Justine - Dr. Monia Marzouki
IWK - Dr. Craig Erker
Stollery Children's Hospital - Dr. Sarah McKillop
Centres
Medical contact

Dr. Daniel Morgenstern

daniel.morgenstern@sickkids.ca

Social worker/patient navigator contact

Karen Fung 

karen.fung@sickkids.ca

Clinical research contact

New Agent and Innovative Therapies (NAIT) 

nait.info@sickkids.ca

 

Medical contact
Rebecca Deyell

 

Social worker/patient navigator contact
Ilana Katz 

 

Clinical research contact
Hem/Onc/BMT Clinical Trials Unit

 

Medical contact
Dr. Magimairajan Vanan
Social worker/patient navigator contact
Rhéanne Bisson
 
Clinical research contact
Rebekah Hiebert
Megan Ridler
Kathy Hjalmarsson

 

 

Medical contact
Raoul Santiago
 
Social worker/patient navigator contact
Isabelle Audet
 
Clinical research contact
Barbara Desbiens
 

 

Medical contact
Dr. Craig Erker
Dr. Conrad Fernandez 
Dr. Ketan Kulkarni 
 
Social worker/patient navigator contact
Rhonda Brophy
 
Clinical research contact
Tina Bocking
 
Medical contact
Dr. Sarah McKillop
Dr. Sunil Desai

 

 

Social worker/patient navigator contact
Danielle Sikora
 Michelle Woytiuk 
Jaime Hobbs
Clinical research contact
Amanda Perreault
Medical contact
Dr. Henrique Bittencourt
Dr. Monia Marzouki
Dr. Sebastien Perreault (neuro-onc)
 
Social worker/patient navigator contact
Marie-Claude Charrette
 
Clinical research contact
Marie Saint-Jacques
 

 

 

Study Description

 

 

This clinical trial is testing a new treatment for children and young adults with aggressive brain tumors, including DIPG and high grade glioma with a specific genetic change (H3 K27M mutation). The treatment combines standard radiation therapy with a new medicine called selinexor, which may help stop cancer cells from growing and shrink tumors. Patients receive radiation for 5-7 weeks and take selinexor pills weekly during and after radiation for up to two years. The study will first find the safest dose of selinexor and then test how well it works. MRIs and follow-up visits help monitor progress. Researchers hope this treatment will improve outcomes for these difficult-to-treat brain tumors.

NOTE: Enrollment for DIPG and DMG has been discontinued. This study is only opened for patients with HGG without a H3 K27M mutation. 

Inclusion Criteria

Pre-Enrollment

  1. Age: Patients must be 25 years old or younger.
  2. Diagnosis: Must have a newly diagnosed high-grade glioma (HGG) that hasn’t spread.
  3. Consent: A parent or guardian, or the patient, must sign a consent form.
  4. Samples (non-DIPG tumours): Tumour samples from surgery or biopsy need to be submitted soon after the procedure (ideally within 5 days).

Main Enrollment

  1. Age: Patients must be between 1 and 21 years old.
  2. Diagnosis:
    • DIPG: Must meet specific imaging or biopsy criteria. CLOSED
    • HGG: Must be newly diagnosed, without certain genetic mutations. OPEN
  3. Patients need to be in good overall health with normal lab results and no severe symptoms.
  4. Enrollment must happen within 31 days of diagnosis or surgery.
  5. A signed consent form is required.

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team. 

BCC015 - Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

Open

BCC015 - Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

Go to Health Care Provider version

DiagnosisNeuroblastomaStudy StatusOpen
PhaseII
AgeChild, Adult - (up to 31 years)RandomisationNO
Line of treatmentDisease relapse or progression
Routes of Treatment AdministrationEtoposide: oral DFMO: oral
Last Posted Update2025-08-27
ClinicalTrials.gov #NCT04301843
International Sponsor
Giselle Sholler
Principal Investigators for Canadian Sites
Montreal Children's Hospital – Dr. Jitka Stankova
CancerCare Manitoba – Dr. Ashley Chopek
CHU Ste-Justine – Dr. Pierre Teira
CHU Sherbrooke - Dr. Josée Brossard
Alberta Children's Hospital – Dr. Melanie Finkbeiner
CHU de Quebec - Dr. Bruno Michon
Janeway Hospital – Dr. Paul Moorehead
Centres
Medical contact
Clinical Research Unit
 
Social worker/patient navigator contact
Clinical Research Unit
 
Clinical research contact
Stephanie Badour
 
Medical contact
Dr. Magimairajan Vanan
Social worker/patient navigator contact
Rhéanne Bisson
 
Clinical research contact
Rebekah Hiebert
Megan Ridler
Kathy Hjalmarsson

 

 

Medical contact
Dr. Henrique Bittencourt
Dr. Monia Marzouki
Dr. Sebastien Perreault (neuro-onc)
 
Social worker/patient navigator contact
Marie-Claude Charrette
 
Clinical research contact
Marie Saint-Jacques
 
Medical contact
Dr. Victor Lewis

 

Social worker/patient navigator contact
Wendy Pelletier
Clinical research contact
Debra Rich
Medical contact
Raoul Santiago
 
Social worker/patient navigator contact
Isabelle Audet
 
Clinical research contact
Barbara Desbiens
 

 

Medical contact
Dr. Josee Brossard 
Social worker/patient navigator contact
Please Contact Site Directly
 
Clinical research contact
Please Contact Site Directly 
 

 

 

Study Description

This study is to assess the effectiveness of a drug called Difluoromethylornithine (DFMO) in combination with etoposide for patients with neuroblastoma that has come back, or is not responidng to current treatment. DFMO is a medication taken by mouth. It is an blocker of ornithine decarboxylase, an enzyme involved with polyamine biosynthesis in the cancer cells, including neuroblastoma cells. 

Inclusion Criteria
  • Patients less than 31 years of age 
  • Diagnosis of neuroblastoma that has come back or is not responding to treatment 
  • Patients can have active or no active disease at the time of study start
  • Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team.

 

LCH 20C05 - A Phase I Clinical Trial of Neo-antigen Heat Shock Protein Vaccine (rHSC-DIPGVax) in Combination With Checkpoint Blockade for the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma in Childhood

Open

LCH 20C05 - A Phase I Clinical Trial of Neo-antigen Heat Shock Protein Vaccine (rHSC-DIPGVax) in Combination With Checkpoint Blockade for the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma in Childhood

Go to Health Care Provider version

DiagnosisDiffuse Intrinsic Pontine Glioma (DIPG), Diffuse Midline Glioma, H3 K27M-MutantStudy StatusOpen
PhaseI
Age12 Months to 18 YearsRandomisationNO
Line of treatmentFirst line treatment
Routes of Treatment AdministrationBiological: rHSC-DIPGVax (vaccine) Drug: Balstilimab Drug: Zalifrelimab
Last Posted Update2025-08-27
ClinicalTrials.gov #NCT04943848
International Sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Principal Investigators for Canadian Sites
Alberta Children's Hospital - Dr. Aru Narendran
Centres
Medical contact
Dr. Victor Lewis

 

Social worker/patient navigator contact
Wendy Pelletier
Clinical research contact
Debra Rich

 

 

Study Description

This study is testing a new treatment for children with DIPG or DMG brain tumors who have recently finished radiation. The treatment combines a vaccine (rHSC-DIPGVax) with two medicines, BALSTILIMAB and ZALIFRELIMAB. The main goal is to see if this combination is safe and can be tolerated. Patients may join if they were diagnosed with DIPG or DMG and completed radiation about 6–10 weeks before entering the study.

Inclusion Criteria
  • Participants must be 12 months - 18 years old with newly diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG) 
  • Must have measurable tumor on scans
  • Body size (BSA) must be at least 0.35 m²
  • Must be up and about at least 50% of waking hours 

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team.

MK-9999-01A/​LIGHTBEAM-U01 - LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors

Open

MK-9999-01A/​LIGHTBEAM-U01 - LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors

Go to Health Care Provider version

DiagnosisB-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing SarcomaStudy StatusOpen
PhaseI/II
Age6 Months to 25 YearsRandomisationNO
Line of treatmentFirst line treatment, Disease relapse or progression
Routes of Treatment AdministrationBiological: Zilovertamab vedotin (IV) Other Names: MK-2140, VLS-101
Last Posted Update2025-08-26
ClinicalTrials.gov #NCT06395103
International Sponsor
Merck Sharp & Dohme LLC
Principal Investigators for Canadian Sites
Montreal Children's Hospital - Dr. Catherine Vézina
Centres
Medical contact
Clinical Research Unit
 
Social worker/patient navigator contact
Clinical Research Unit
 
Clinical research contact
Stephanie Badour
 

 

 

Study Description

This study is part of a larger research project. The goal is to see if a new treatment called zilovertamab vedotin is safe and works well for children and young adults whose cancer has come back (relapsed) or did not get better with treatment (refractory).

The study is for patients with B-ALL (a type of leukemia that starts in the bone marrow and blood), DLBCL or Burkitt lymphoma (fast-growing blood cancers that affect the lymph nodes or organs), neuroblastoma (a cancer that starts in nerve cells, usually in young children), or Ewing sarcoma (a cancer of the bones or nearby tissue, often in children and teens).

Inclusion Criteria
  • Participant must have one of the following diagnoses:
    • Blood cancers: children with a type of leukemia called B-ALL and children with certain fast-growing lymphomas (DLBCL or Burkitt lymphoma) OR
    • Solid tumors: children with neuroblastoma or children with Ewing sarcoma

Other inclusion or exclusion criteria may apply and will be discussed with you by the study team.